Pulmonary Cell News Volume 8.41 | Oct 24 2019

TOP STORY

Characterization of Orally Efficacious Influenza Drug with High Resistance Barrier in Ferrets and Human Airway Epithelia

Therapeutic oral dosing of influenza virus-infected ferrets reduced group pandemic 1 and group 2 seasonal influenza A shed virus load by multiple orders of magnitude and alleviated fever, airway epithelium histopathology, and inflammation, whereas postexposure prophylactic dosing was sterilizing. [Sci Transl Med] Abstract | Editorial

(Ranked by impact factor of the journal)

Anti-Inflammatory Mechanisms of the Novel Cytokine Interleukin-38 in Allergic Asthma

Human bronchial epithelial cells and eosinophils were co-cultured upon stimulation with the viral RLR ligand poly (I:C)/LyoVec or infection-related cytokine TNF-α to induce expression of cytokines/chemokines/adhesion molecules. House dust mite-induced allergic asthma and humanized allergic asthma NOD/SCID murine models were established to assess anti-inflammatory mechanisms in vivo. [Cell Mol Immunol] Abstract

Jagged and Delta Ligands Control Distinct Events during Airway Progenitor Cell Differentiation

Jag ligands had a major impact in balancing distinct cell populations in conducting airways, but had no role in establishment of domains and cellular abundance in the neuroendocrine (NE) microenvironment. Dll ligands were crucial in restricting cell fate and size of NE bodies and showed an overlapping role with Jag in differentiation of NE-associated secretory cells. [eLife] Full Article

Mitochondrial Dysfunction Increases Pro-Inflammatory Cytokine Production and Impairs Repair and Corticosteroid Responsiveness in Lung Epithelium

Researchers investigated whether a mitochondrial defect may contribute to increased lung epithelial pro-inflammatory responses, impaired epithelial repair and reduced corticosteroid sensitivity as observed in COPD. [Sci Rep] Full Article

LUNG CANCER

Macrophages Reprogrammed by Lung Cancer Microparticles Promote Tumor Development via Release of IL-1β

Investigators showed that lung cancer microparticles induced macrophages to release a key proinflammatory cytokine, IL-1β, thus promoting lung cancer development. [Cell Mol Immunol] Abstract

In Silico Identification of Thiostrepton as an Inhibitor of Cancer Stem Cell Growth and an Enhancer for Chemotherapy in Non–Small-Cell Lung Cancer

In non-small-cell lung cancer cells thiostrepton inhibited cancer stem cell growth in vitro and reduced protein expression of cancer stemness markers, including CD133, Nanog and Oct4A. [J Cell Mol Med] Full Article

The TWIST1-Centered Competing Endogenous RNA Network Promotes Proliferation, Invasion, and Migration of Lung Adenocarcinoma

The authors found that TWIST1/SLC12A5/ZFHX4 were all upregulated in lung adenocarcinoma and were associated with poorer prognosis. SLC12A5 and ZFHX4 facilitated proliferation, migration, and invasion in vivo and in vitro, and their effects were reversed by miR-194–3p and miR-514a-3p, respectively. [Oncogenesis] Full Article

Unbiased Peptoid Combinatorial Cell Screen Identifies Plectin Protein as a Potential Biomarker for Lung Cancer Stem Cells

Scientists showed both genotypic and phenotypic correlations between plectin and lung cancer stem cells, as well as association of high plectin mRNA expression with poor patient survival in lung adenocarcinoma. [Sci Rep] Full Article

miR-335-5p Inhibits TGF-β1-Induced Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer via ROCK1

Over-expresion of miR-335-5p significantly inhibited TGF-β1-mediated non-small cell lung cancer migration and invasion. [Respir Res] Full Article

Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News.

Targeting Proteases in Cystic Fibrosis Lung Disease: Paradigms, Progress, and Potential

Scientists review the current knowledge and emerging concepts of the role of host proteases in the pathogenesis of CF lung disease and their potential as therapeutic targets. [Am J Respir Crit Care Med] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

CheckMate -9LA, a Phase III Trial Evaluating Opdivo (Nivolumab) plus Low-Dose Yervoy (Ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer

Bristol-Myers Squibb Company announced that CheckMate -9LA, a pivotal Phase III trial evaluating Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy for the first-line treatment of advanced non-small cell lung cancer, met its primary endpoint of superior overall survival at a pre-specified interim analysis. [Bristol-Myers Squibb Company] Press Release

FDA Approves TRIKAFTA to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated announced the FDD has approved TRIKAFTA^™ for the treatment of CF in people ages 12 years and older who have at least one F508del mutation in the CF transmembrane conductance regulator gene, the most common CF-causing mutation. [Vertex Pharmaceuticals Incorporated] Press Release

Vertex Receives European CHMP Positive Opinion for KALYDECO^® (Ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age

Vertex Pharmaceuticals Limited announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO^®, to include use in infants with CF ages 6 months to less than 12 months who have one of the following mutations in their CF transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. [Vertex Pharmaceuticals Limited] Press Release

After Years of Battling, Vertex and the UK Reach a Deal for Cystic Fibrosis Medicines

After years of frustration, Vertex Pharmaceuticals struck a deal with the UK government to supply its CF medicines, capping an end to a dispute that had become a symbol of the growing clash between cash-strapped governments and drug makers over the rising prices for medicines. [STAT News] Editorial

Trump Names Seven to Revived Presidential Science Advisory Panel

Thirty-three months after taking office, President Donald Trump has chosen a group of business leaders to advise him on science and technology policy. [ScienceInsider] Editorial

NEW FGF Signaling: Understanding Function and Devising Therapeutic Tools
May 10-15, 2020
Tuscany, Italy

Visit our events page to see a complete list of events in the community.

NEW Research Assistant – Pulmonary Research (Philipps University of Marburg)

NEW Postdoctoral Research Fellow – Small Cell Lung Cancer (University Hospital of Cologne)

NEW PhD Studentship – Small Cell Lung Cancer (Cancer Research UK Manchester Institute)

Postdoctoral Training Fellow – Machine Learning (Institute of Cancer Research)

Postdoctoral Research Fellow – Lung Development and Disease (Center for Regenerative Medicine)

Research Fellow – Lung Cancer (Dana-Farber Cancer Institute)

Faculty Position – Pulmonary and Critical Care Medicine (Mayo Clinic Comprehensive Cancer Center)

Research Scientist – Fibrosis (Gilead Sciences, Inc.)

Postdoctoral Positions – Sepsis and Pulmonary Injury (University of Maryland)

Postdoctoral Fellowship – Lung Epithelium (Boston University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.